Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
INCYTE CORP | President, R&D | Common Stock | 221K | $14.2M | $64.25 | Jul 15, 2024 | Direct |
Rubius Therapeutics, Inc. | Director | Restricted Stock Units | 75K | Jan 31, 2023 | Direct | ||
Rubius Therapeutics, Inc. | Director | Common Stock | 66.1K | Feb 1, 2023 | Direct | ||
INCYTE CORP | President, R&D | Employee Stock Option (right to buy) | 44.4K | Jul 15, 2024 | Direct | ||
Fusion Pharmaceuticals Inc. | Director | Stock Option (Right to Buy) | 0 | Jun 4, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
INCY | INCYTE CORP | Jul 15, 2024 | 3 | -$48.1K | 4 | Jul 17, 2024 | President, R&D |
FUSN | Fusion Pharmaceuticals Inc. | Jun 4, 2024 | 5 | $0 | 4 | Jun 4, 2024 | Director |
INCY | INCYTE CORP | Jan 18, 2024 | 1 | $0 | 4 | Jan 22, 2024 | President, R&D |
INCY | INCYTE CORP | Jul 14, 2023 | 2 | $0 | 4 | Jul 18, 2023 | President, R&D |
FUSN | Fusion Pharmaceuticals Inc. | Jun 14, 2023 | 1 | $0 | 4 | Jun 14, 2023 | Director |
INCY | INCYTE CORP | Jun 7, 2023 | 0 | $0 | 3 | Jun 7, 2023 | President, R&D |
INCY | INCYTE CORP | Jun 5, 2023 | 1 | $0 | 4/A | Jun 21, 2023 | President, R&D |
RUBY | Rubius Therapeutics, Inc. | Feb 1, 2023 | 1 | -$2.11K | 4 | Feb 1, 2023 | Director |
RUBY | Rubius Therapeutics, Inc. | Jan 29, 2023 | 5 | -$1.74K | 4 | Jan 31, 2023 | Director |
FUSN | Fusion Pharmaceuticals Inc. | Jun 14, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director |
RUBY | Rubius Therapeutics, Inc. | Jan 29, 2022 | 5 | -$44.2K | 4 | Feb 1, 2022 | CEO and President, Director |
RUBY | Rubius Therapeutics, Inc. | Dec 31, 2021 | 2 | $0 | 5 | Feb 14, 2022 | CEO and President, Director |
FUSN | Fusion Pharmaceuticals Inc. | Jun 4, 2021 | 1 | $0 | 4 | Jun 7, 2021 | Director |